CASC2 and non-small cell lung carcinoma: CASC2 negatively regulated miR-18a and miR-21, thus modulating PTEN/phosphoinositide 3-kinase (PI3K)/Akt pathway and cisplatin-induced viability inhibition in non-small cell lung cancer (32).